MiMedx Group Stock Price, News & Analysis (NASDAQ:MDXG) $7.89 -0.03 (-0.38%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$7.73▼$7.9450-Day Range$5.70▼$7.9252-Week Range$2.43▼$8.60Volume612,935 shsAverage Volume671,642 shsMarket Capitalization$918.24 millionP/E RatioN/ADividend YieldN/APrice Target$11.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media MiMedx Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside47.9% Upside$11.67 Price TargetShort InterestHealthy3.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingAcquiring Shares$35,800 Bought Last QuarterProj. Earnings Growth277.78%From $0.09 to $0.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.64 out of 5 starsMedical Sector162nd out of 949 stocksSurgical & Medical Instruments Industry22nd out of 95 stocks 3.5 Analyst's Opinion Consensus RatingMiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.67, MiMedx Group has a forecasted upside of 47.9% from its current price of $7.89.Amount of Analyst CoverageMiMedx Group has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.72% of the float of MiMedx Group has been sold short.Short Interest Ratio / Days to CoverMiMedx Group has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in MiMedx Group has recently decreased by 12.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMiMedx Group does not currently pay a dividend.Dividend GrowthMiMedx Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDXG. Previous Next 2.2 News and Social Media Coverage News SentimentMiMedx Group has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MiMedx Group this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for MDXG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiMedx Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,800.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.90% of the stock of MiMedx Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.85% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MiMedx Group are expected to grow by 277.78% in the coming year, from $0.09 to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiMedx Group is -394.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiMedx Group is -394.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About MiMedx Group Stock (NASDAQ:MDXG)MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.Read More MDXG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDXG Stock News HeadlinesNovember 25, 2023 | morningstar.comMiMedx Group Inc MDXGNovember 19, 2023 | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Shares Up 5.4%November 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 13, 2023 | finance.yahoo.comMIMEDX to Participate in Upcoming Investor ConferencesNovember 2, 2023 | finance.yahoo.comMIMEDX to Highlight Published Data at SAWC FallNovember 2, 2023 | finance.yahoo.comLoss-Making MiMedx Group, Inc. (NASDAQ:MDXG) Set To BreakevenNovember 1, 2023 | msn.comMizuho Maintains Mimedx Group (MDXG) Buy RecommendationNovember 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG) and Repligen (RGEN)November 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 31, 2023 | msn.comMDXG: Xenografts and Synthetics Options for ExpansionOctober 31, 2023 | finance.yahoo.comMiMedx Group, Inc. (NASDAQ:MDXG) Q3 2023 Earnings Call TranscriptOctober 31, 2023 | finance.yahoo.comQ3 2023 MiMedx Group Inc Earnings CallOctober 31, 2023 | finanznachrichten.deMiMedx Group, Inc: MIMEDX Announces Third Quarter 2023 Operating and Financial ResultsOctober 30, 2023 | msn.comMiMedx Group Non-GAAP EPS of $0.05 in-line, revenue of $81.71M beats by $3.77MOctober 30, 2023 | finance.yahoo.comMiMedx Group Inc (MDXG) Reports 20.7% Increase in Q3 2023 Net SalesOctober 28, 2023 | msn.comCraig-Hallum Initiates Coverage of Mimedx Group (MDXG) with Buy RecommendationOctober 27, 2023 | msn.comMiMedx Group Q3 Earnings PreviewOctober 16, 2023 | finance.yahoo.comMIMEDX to Host Third Quarter 2023 Operating and Financial Results Conference Call on October 30October 6, 2023 | finance.yahoo.comInvesting in MiMedx Group (NASDAQ:MDXG) a year ago would have delivered you a 161% gainOctober 4, 2023 | seekingalpha.comUnraveling MiMedx's Surgical Precision In GrowthSeptember 26, 2023 | finance.yahoo.comMIMEDX Announces Launch of EPIEFFECT™August 31, 2023 | msn.comMimedx Group (MDXG) Price Target Increased by 19.14% to 12.30August 15, 2023 | finance.yahoo.comMediWound Announces Collaboration with MIMEDX on EscharEx® Phase III StudyAugust 10, 2023 | seekingalpha.comMiMedx Group, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 2, 2023 | finance.yahoo.comMDXG: Beat and a RaiseAugust 2, 2023 | finance.yahoo.comQ2 2023 MiMedx Group Inc Earnings CallAugust 2, 2023 | finanznachrichten.deMiMedx Group, Inc: MIMEDX Announces Second Quarter 2023 Operating and Financial ResultsSee More Headlines Receive MDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2023Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDXG CUSIPN/A CIK1376339 Webwww.mimedx.com Phone(770) 651-9100Fax678-384-6741Employees867Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$12.00 Low Stock Price Target$11.00 Potential Upside/Downside+47.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio87.67 P/E GrowthN/ANet Income$-30,200,000.00 Net Margins-0.82% Pretax Margin1.60% Return on EquityN/A Return on Assets-0.72% Debt Debt-to-Equity Ratio36.82 Current Ratio3.54 Quick Ratio3.10 Sales & Book Value Annual Sales$267.84 million Price / Sales3.43 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-49.31Miscellaneous Outstanding Shares116,380,000Free Float93,218,000Market Cap$918.24 million OptionableOptionable Beta1.63 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. William F. Hulse IV (Age 49)General Counsel & Chief Administrative Officer Comp: $677.36kDr. Robert Benjamin Stein M.D. (Age 72)Ph.D., President of Regenerative Medicine & Biologics Innovation Comp: $639.28kMr. Joseph H. Capper (Age 59)CEO & Director Mr. Douglas C. Rice CPA (Age 57)Chief Financial Officer Mr. Scott M. Turner (Age 57)Senior Vice President of Operations & Procurement Comp: $493.98kMr. Matthew M. NotarianniHead of Investor RelationsMr. Mark P. Graves (Age 57)Senior VP & Chief Compliance Officer Hilary DixonVice President of Investor Relations & Corporate Strategic CommunicationsMs. Kate SurdezChief Human Resources OfficerDr. David H. Mason Jr. (Age 76)Chief Medical Officer More ExecutivesKey CompetitorsAcelyrinNASDAQ:SLRNPliant TherapeuticsNASDAQ:PLRXIntercept PharmaceuticalsNASDAQ:ICPTApogee TherapeuticsNASDAQ:APGEADMA BiologicsNASDAQ:ADMAView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 10,573 shares on 11/24/2023Ownership: 0.044%Cannell Capital LLCBought 1,173,506 shares on 11/22/2023Ownership: 1.954%Graham Capital Management L.P.Bought 21,548 shares on 11/22/2023Ownership: 0.019%Rice DougBought 5,000 shares on 11/21/2023Total: $35,800.00 ($7.16/share)Walleye Capital LLCSold 113,380 shares on 11/21/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions MDXG Stock Analysis - Frequently Asked Questions Should I buy or sell MiMedx Group stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDXG shares. View MDXG analyst ratings or view top-rated stocks. What is MiMedx Group's stock price target for 2024? 3 Wall Street analysts have issued 1 year target prices for MiMedx Group's stock. Their MDXG share price targets range from $11.00 to $12.00. On average, they expect the company's share price to reach $11.67 in the next year. This suggests a possible upside of 47.9% from the stock's current price. View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts. How have MDXG shares performed in 2023? MiMedx Group's stock was trading at $2.78 on January 1st, 2023. Since then, MDXG stock has increased by 183.8% and is now trading at $7.89. View the best growth stocks for 2023 here. When is MiMedx Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our MDXG earnings forecast. How were MiMedx Group's earnings last quarter? MiMedx Group, Inc. (NASDAQ:MDXG) announced its earnings results on Monday, October, 30th. The company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. The business earned $81.71 million during the quarter, compared to the consensus estimate of $76.69 million. What ETF holds MiMedx Group's stock ? Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio. Who are MiMedx Group's major shareholders? MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional investors include Cannell Capital LLC (1.95%), Richmond Brothers Inc. (1.27%), Charles Schwab Investment Management Inc. (0.92%), Northern Trust Corp (0.92%), Federated Hermes Inc. (0.72%) and Royal Bank of Canada (0.71%). Insiders that own company stock include Mark Graves, Peter M Carlson, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan. View institutional ownership trends. How do I buy shares of MiMedx Group? Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MDXG) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.